Hantavirus vaccine in 2026?

📡 Polymarket: 6%
Two different numbers on purpose: Polymarket's is the outside reference, Profet's is what actually moves credits here.

3.50Ᵽ best bid · 7.50Ᵽ best ask

Polymarket's price is shown for reference only -- this platform's own order book sets its own price, and the two can diverge.

Log in to trade this market.

Order book

How much do you disagree with this price?

Pick 1 (barely) to 5 (strongly) -- a pure sentiment vote, not a trade, not tied to credits.

Log in to add your own rating.

No one's rated this yet -- be the first.

Source

Polymarket (via UMA optimistic oracle) ✓ Verified source

Event cutoff

Jan. 1, 2027, 4:59 a.m.

Rules

This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".

The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.